RUPATADINE
ApprovedSmall molecule
RUPATADINE is one of 113 small molecule programs targeting Urticaria. It is currently in Approved.
5
Indications
13
Total Trials
3
Active Trials
112
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
460 competitors in Ulcerative Colitis
#DrugCompanyPhaseTrials
1Orencia
Bristol-Myers SquibbPhase 3
Mounjaro
Eli LillyPhase 3
RUPATADINE
JJ. Uriach and Company
Approved
Purinethol
SStason
Phase 3
Diosmin
TTanta University
Phase 3
RPC1063
Bristol-Myers SquibbPhase 3
SPD476
TakedaPhase 3
Etrolizumab
RochePhase 3
Simponi
Johnson & JohnsonPreclinical
CT-P13 SC (infliximab)
CCelltrion
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Idiopathic Urticaria2 trials
Ulcerative Colitis1 trial
Rupatadine in Patients With Ulcerative Colitis
Recruiting·—·Phase 2·NCT07064707·60 enrolled
Fasting Conditions1 trial
7 more indications
Hepatic Impairment1 trial
Cold Urticaria1 trial
Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria
Completed·—·Phase 2·NCT01605487·24 enrolled
Renal Impairment1 trial
Driving1 trial
Urticaria1 trial
Chronic Urticaria - Long Term Assessment of Effects of Rupatadine
Terminated·—·Phase 3·NCT02358265·192 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RUPATADINE. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- JJ. Uriach and Company